Bleeding outcomes with ticagrelor versus clopidogrel in patients with the acute coronary syndrome; a focused analysis from the multicenter CREA ARIAM Andalucia registry

Bleeding outcomes with ticagrelor versus clopidogrel in patients with the acute coronary syndrome; a focused analysis from the multicenter CREA ARIAM Andalucia registry The question that usually arises is that, “What is the incidence, types, timing, and prognostic relevance of major bleeding events in ACS patients treated with ticagrelor or clopidogrel in contemporary practice”? What we already know is that with the use of various antithrombotic agents in acute coronary syndrome (ACS), bleeding has emerged as an important safety concern. Moreover, haemorrhagic complications have been strongly linked with subsequently mortality in this clinical scenario. A total of 2070 patients with ACS were enrolled in the prospective, observational, multicentre trial. The participants received a 12-month DAPT course with clopidogrel or ticagrelor. Major bleeding was assessed using the Bleeding Academic Research Consortium (BARC). All bleeding episodes were analysed accounting for death. Among 2070 patients surviving hospital discharge, 5.3% (106) of them experienced a major bleeding event at the median time of 92 days and most events were classified as BARC type 3a with 2 fatal bleeds. In 53% of the cases, the site was gastrointestinal bleeding followed by 12% cases of intracranial bleeding. Ticagrelor was associated with an increased but not statistically significant risk of major bleeding compared with clopidogrel. To conclude, the most common bleeding site was gastrointestinal site followed by intracranial haemorrhage and the ticagrelor use was not associated with a significantly increased risk of major bleeding. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.